Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Birch pollen allergy vaccine tablet - ALK-Abello

Next Previous
Search
Drug Profile

Birch pollen allergy vaccine tablet - ALK-Abello

Alternative Names: Betula Verrucosa allergen extract; ITULAZAX; Oralgen Birch Pollen; SLIT birch pollen extract; SLITone Birch; SLITonePLUS Birch; SQ tree SLIT-tablet

Latest Information Update: 29 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ALK-Abello
  • Class Allergens; Peptide vaccines; Peptides; Skin disorder therapies; Tree pollen allergy immunotherapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Registered Allergic conjunctivitis; Allergic rhinitis; Allergic rhinoconjunctivitis

Most Recent Events

  • 24 Apr 2025 Registered for Allergic conjunctivitis (In adolescents, In children, Treatment-experienced) in Liechtenstein, Norway, Iceland and European Union (Sublingual)
  • 24 Apr 2025 Registered for Allergic rhinitis (In adolescents, In children, Treatment-experienced) in Liechtenstein, Norway, Iceland and European Union (Sublingual)
  • 23 Apr 2025 ALK-Abello expects approval of the birch pollen vaccine tablet (In children, In adolescents) in Europe and Canada (Sublingual, Tablet), in 2025/2026

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top